AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Elicio Therapeutics, Inc. Director's Dealing 2021

Dec 17, 2021

33784_dirs_2021-12-17_4538852a-4a65-42dd-9597-c36d37d72856.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Angion Biomedica Corp. (ANGN)
CIK: 0001601485
Period of Report: 2021-06-24

Reporting Person: Venkatesan Jay (Director, See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-24	Common Stock	F	41091	$13.78	Disposed	1239257	Direct
2021-12-15	Common Stock	P	77604	$2.4091	Acquired	1316861	Direct

Footnotes

F1: The shares were withheld to satisfy tax or other government withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs").